Reactivity of expanded panel of CD20 mAbs
Group . | AxP reactivity . | Antibody designation . | Homotypic aggregation . | CD20 translocation . |
---|---|---|---|---|
I | None | CAT 13.6E126 | − | ++++ |
II | Weak | 2H76, 1C0-1652 | − | ++++, ++ |
AT802 | ++++ | ++++ | ||
III | Intermediate | 1F56, B-H202, MEM-972 | − | +++ |
IV | High | B16, Bly12 | ++++ | − |
Rituxan3 | ++ | ++++ | ||
NK12, PDR782, F4B13661, LT205, L275, CAT 13.7H82 | − | +++ to ++++ |
Group . | AxP reactivity . | Antibody designation . | Homotypic aggregation . | CD20 translocation . |
---|---|---|---|---|
I | None | CAT 13.6E126 | − | ++++ |
II | Weak | 2H76, 1C0-1652 | − | ++++, ++ |
AT802 | ++++ | ++++ | ||
III | Intermediate | 1F56, B-H202, MEM-972 | − | +++ |
IV | High | B16, Bly12 | ++++ | − |
Rituxan3 | ++ | ++++ | ||
NK12, PDR782, F4B13661, LT205, L275, CAT 13.7H82 | − | +++ to ++++ |
Superscripts indicate the number of times each antibody was tested for reactivity against the m/h AxP chimera (construct C). At least 2 homotypic aggregation and translocation experiments were performed for each antibody, and were scored as described in “Materials and methods.”